DUBLIN--(BUSINESS WIRE)--The "Growth Opportunities in Gene Therapy, Automated Bioanalytics, and Biomarker Platforms" report has been added to ResearchAndMarkets.com's offering.
The research provides technological insights across inflammation, infectious diseases, and microbiomics.
The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Innovations in Life Sciences, Health & Wellness from:
- Freeline Therapeutics, UK
- Nodthera, UK
- CEM Corporation, US
- Elementar Analysensysteme Gmbh, Germany
- Apitope Technology Ltd., UK
- MGB Biopharma Ltd., UK
- Reviral Ltd., UK
- Mina Therapeutics Limited, UK
- Abcordia Ltd., UK
- Genome Medical, US
- Biogen, US
- Hong Kong University of Science and Technology, Hong Kong
- Amryt, UK
- Uniqure NV, Netherlands
- Caspr Biotech, Argentina
- Travecta Therapeutics, Singapore
- Wistar Institute, US
- E-Therapeutics, UK
- Enterome, France
- Elisa Technologies, US
- Cutiss, Switzerland
- Beckley Psytech, UK
- Pharnext, France
- Children's Hospital of Philadelphia, US
- Incelldx, US
- Biochrom, UK
For more information about this report visit https://www.researchandmarkets.com/r/tkufmb
